Oncolin Therapeutics, Inc., (OTCBB:OCOL) is pleased to announce that Dr
Randall K. Johnson has agreed to join the Scientific Advisory Board of
the company joining a growing number of illustrious oncologists and
cancer drug developers. Dr Johnson began his career as section Head of
the Experimental Chemotherapy at the National Cancer Institute. Most of
his accomplishments occurred over more than twenty years at Glaxo
SmithKline where he held various senior positions in oncology
culminating in Oncology Group Director. Among the many accomplishments
during his tenure was the development of Topotecan which continues to be
a major drug used in cancer therapy today. For the past five years Dr
Johnson has consulted for numerous drug and biotech companies and is a
member of many Scientific Advisory Boards and clinical advisory Boards
for oncology based companies.
“We are very excited to have someone with Dr
Johnson’s commercial oncology development
experience as an advisor and consultant to our company. Once we complete
our scientific advisory board we will have one of the top SABs in the
nation and it will be staffed with some of the leading inventors and
innovators in the cancer treatment space,”
said Dr Donald Picker, President and COO.
Recent News
Oncolin announces its lead technology has shown to be effective in
treating cancer in animal models.
Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option
Patents Covering the Composition and Use of Genistein Analogs for Cancer
Treatment
Oncolin has recently announced that is has obtained an exclusive option
agreement with the Pharmaceutical Research Institute of Warsaw, Poland
which provides the company the right to license the use of Genistein
analogs for cancer treatment.
About Oncolin Therapeutics, Inc.
Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a
publicly traded biopharmaceutical company that engages in the discovery,
development and commercialization of novel selective anticancer
therapies. Additional information about Oncolin can be found on the web
at www.oncolinthera.com.
Safe Harbor Statement
This press release contains statements that may constitute
forward-looking statements, including the company's ability to
successfully acquire and develop technologies that are and may be
acquired. These statements are based on current expectations and
assumptions and involve a number of uncertainties and risks that could
cause actual results to differ materially from those currently expected.
For additional information about Oncolin's future business and financial
results, refer to Oncolin's Quarterly Report on Form 10-QSB for the
quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the
year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation
to update any forward-looking statement that may be made from time to
time by or on behalf of the company, whether as a result of new
information, future events or otherwise.
|